NEW PROWL Registry data has been unleashed !
Capture peripheral arterial clot
—on the spot
With a combined vessel diameter range of 2–10mm, the Pounce™ Thrombectomy Platform provides a standalone solution for rapid removal of peripheral arterial thrombi and emboli throughout the lower and upper extremities.
2–10mm
COMBINED VESSEL DIAMETER RANGE
2–4mm
3.5–6mm
5.5–10mm
Rapid removal of acute or chronic thrombi or emboli without thrombolysis
NO aspiration used for clot removal–minimizes blood loss
NO capital equipment
NEW CASE REPORT
5.5–10mm vessel diameter
Removing subacute
CFA thrombus
The Pounce™ XL Thrombectomy System demonstrated versatility by enabling the deployment of a .035” PTA balloon catheter over the basket wire to help loosen the wall-adherent material.
Post-Pounce XL
System angiogram
Pre-procedure
angiogram
ENDOVASCULAR TODAY
READ THE ARTICLE
The Pounce™ Thrombectomy Platform: Physician-designed for simplicity and effectiveness
The Pounce™ Thrombectomy Platform allowed for significant efficacy with high procedural success.1
SAFETY
2.0 24.1min
Median Number of Passes per Patient
N = 160 Patients
Device
Time
SUCCESS
91.7%
Procedure
Success
9 Sites
SAFETY
ZERO 0.6%
Device-Related Embolizations*
DATA UNLEASHED AS OF 11/03/25
New Findings: Decide with Data
(1 in 160)
Device-Related
CD-TLR
SAVINGS
64.4%
Avoided
ICU Time
- Lyden S. Real-world Clinical Outcomes and Case Insights of the Novel Pounce™ Thrombectomy Platform. 23rd Annual Vascular InterVentional Advances (VIVA); November 3rd, 2025; Las Vegas, Nevada.
- Distal embolization requiring surgical procedure or obstructing one of the major downstream vessels >70% (at the end of the procedure).
DATA UNLEASHED
AS OF 11/03/25
New Findings:
Decide with Data
The Pounce™ Thrombectomy Platform allowed for significant efficacy with high procedural success.1
N = 160 Patients
9 Sites
SPEED
2.0 24.1min
Median Number of Passes per Patient
Device
Time
SUCCESS
91.7%
Procedure Success
SAFETY
ZERO 0.6%
Device-Related Embolizations*
(1 in 160)
Device-Related
CD-TLR
SAVINGS
64.4%
Avoided ICU Time
- Lyden S. Real-world Clinical Outcomes and Case Insights of the Novel Pounce™ Thrombectomy Platform. 23rd Annual Vascular InterVentional Advances (VIVA); November 3rd, 2025; Las Vegas, Nevada.
- Distal embolization requiring surgical procedure or obstructing one of the major downstream vessels >70% (at the end of the procedure).
When minutes matter – remove acute or chronic thrombi or emboli without aspiration, thrombolytics, or capital equipment with the Pounce™ Thrombectomy Platform.
READ THE SUPPLEMENT
Read the new supplement to learn how top endovascular physicians are capturing peripheral arterial clot–on the spot.
Read past Endovascular Today supplements:
Surmodics Announces Outcomes
from 160 Patients in PROWL Registry Evaluating Pounce™ Thrombectomy Platform in Treatment of Real-World
Limb Ischemia Presentations
Latest press releases
Surmodics Announces Results from
Sex-Specific Analysis of the PROWL Registry
Study of Real-World Limb Ischemia
Patients Treated with the Pounce™
Thrombectomy Platform
Surmodics Announces Commercial Release of Pounce™ XL Thrombectomy System, Enabling Rapid Non-Surgical Clot Removal in Iliac and Femoral Arteries
Read the single-center study
A published single-center study out of South Carolina evaluated the safety and efficacy of the Pounce system to restore pulsatile flow to ischemic lower extremities.
Intended Use:
The Pounce™ Thrombectomy System is intended for the non-surgical removal of thrombi and emboli from the peripheral arterial vasculature.
Contraindications:
The device is contraindicated for use in patients who cannot receive recommended intravenous anticoagulant therapy.